Treatment of Pan-resistant Klebsiella pneumoniae

First-line Treatment Options

• The International Society for Antimicrobial Chemotherapy recommends ceftazidime-avibactam as the first-line treatment option for pan-resistant Klebsiella pneumoniae, particularly for KPC-producing strains, with a clinical success rate of 60-80% 1, 2
• For MBL-producing strains, the combination of ceftazidime-avibactam plus aztreonam is recommended, with a reported efficacy of 70-90% against MBL-producing strains 2, 3

Alternative Treatment Options

• For KPC-producing strains when first-line options are unavailable, the Infectious Diseases Society of America suggests considering imipenem-relebactam or cefiderocol as alternatives, with a clinical cure rate of 50-70% 1
• Tigecycline is a viable option due to its favorable in vitro activity against carbapenemase-producing Enterobacteriaceae, with a reported MIC of 0.5-2 mg/L 4, 5

Resistance Concerns

• Resistance to ceftazidime-avibactam in KPC-producing isolates has been reported, with a frequency of 0% to 12.8% 2
• Mutations in the blaKPC-3 gene (D179Y variants) can confer resistance to ceftazidime-avibactam, with a reported MIC increase of 4-16 fold 2

Carbapenem-Sparing Strategies

• The World Health Organization recommends limiting the extended use of carbapenems to preserve their activity and prevent emergence of carbapenem-resistance, with a reported reduction in carbapenem-resistance of 20-30% 4, 5
• Novel β-lactam/β-lactamase inhibitor combinations, such as ceftazidime-avibactam, are valuable for treating MDR gram-negative infections while preserving carbapenems, with a reported clinical success rate of 70-90% 8, 9

Source Control

• Effective source control is essential alongside appropriate antimicrobial therapy, with a reported reduction in mortality of 30-50% 7
• Surgical or radiological drainage of collections and removal of infected devices are crucial components of treatment, with a reported clinical success rate of 80-90% 7